Commercialization of GlaxoSmithKline PLC’s first product from its Antigen Specific Cancer Immunotherapy (ASCI) program is still at least several years off, but the company is already commissioning a companion diagnostic for it. It has enlisted Abbott Laboratories Inc.’s Abbott Molecular Inc. to develop a PCR-based test to screen non-small cell lung cancer (NSCLC) tumors for expression of MAGE-A3, an antigen found on NSCLC, melanomas, and other solid tumors. [See Deal] By striking a deal for a screening test this far in advance of commercialization, GSK may be laying the groundwork to address any regulatory concerns around using an enriched clinical trial population, anticipating a data package for approval based on a rapid and probably more responsive clinical trial owing to the use of the screening test, which could allow for lower numbers of patients to be enrolled to prove efficacy.
Like most immunotherapy endeavors, ASCI is a long-term bet for GSK. The firm had been collaborating since 1995 with the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?